• An advanced inhibitor of advanced glycation end-products (A.G.E.s), a major causative factor in diabetic kidney disease;
  • Administration to animal models produces a dramatic protective effect against the onset of diabetic kidney disease;
  • Currently in Phase II trials for diabetic kidney disease;
  • Only 1 drug approved for this disease;
  • Estimated worldwide market potential - greater than $6 billion.

Pyridorin™ is a small molecule drug candidate to treat diabetic kidney disease. This drug candidate addresses
a tremendous medical problem. Four out of every ten patients with Type 1 diabetes, and 15% of patients with Type 2 diabetes will develop kidney disease. Renal replacement therapy with either dialysis or kidney transplantation is often the consequence of diabetic
kidney disease. BioStratum scientists have shown that Pyridorin™ prevents hyperglycemia-induced damage to proteins and tissues, and dramatically retards the progression of kidney disease in animal models of diabetes. Phase I studies are complete, and no serious adverse events were seen, indicating that Pyridorin™ is
a safe drug candidate. Phase II trials are ongoing.

Medicament cialis et viagra generiques en ligne en France.

  • A recombinant type IV collagen derived drug candidate;
  • A potent anti-angiogenesis and anti-tumor agent;
  • Interrupts basal lamina formation;
  • Unique mechanism of action with multi-inhibitory activities;
  • Soon entering clinical trials

Angiocol™ is a recombinant type IV collagen derived
anti-angiogenesis drug candidate that inhibits new blood vessel growth by targeting the assembly and organization of the basal lamina. Without an increased blood supply,
the growth of a tumor is substantially limited. Therapies that inhibit new blood vessel growth are a promising approach for the treatment of cancer. Angiocol™ has demonstrated impressive anti-angiogenic and anti-tumor activity in a wide range of test systems and animal models of cancer. The Company believes that Angiocol's™ unique basal lamina targeted mode of action, which intervenes in
a number of molecular processes important to new blood vessel growth, will make it more effective than other drug candidates that are currently undergoing development in this area. Pre-clinical toxicology studies are underway and Phase I clinical trials are scheduled to begin in 2001.

More on Pyridorin™
More on Angiocol™